At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 92 enrolled
Drug / intervention
Dasatinib +1 moredrug
Likely dose
Dasatinib 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Receptor-Positive or Her2/Neu-Positive Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Dasatinib and Dasatinib 100 mg for Breast Cancer and Metastasis. Completed, enrolled 92 participants across 23 sites in 7 countries.
Detailed Summary
This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced ER+/PR+ or Her2/neu+ breast cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Metastasis
CountriesArgentina, Belgium, France, Italy, Peru, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2006
Enrollment StartDec 2006
Primary CompletionMar 2009
Study CompletionMay 2009
TodayJul 2026
First PostedSep 4, 2006
Enrollment StartDec 1, 2006
Primary CompletionMar 1, 2009
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 19.8 years ago
Interventions
Dasatinibdrug
Tablets, Oral, 70 mg, twice daily, as long as the participant benefits (average \<6 months)
Dasatinib 100 mgdrug
Tablets, Oral, 100mg, twice daily, as long as the participant benefits (average \<6 months)